<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722680</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0106/1712</org_study_id>
    <secondary_id>2017-002320-25</secondary_id>
    <nct_id>NCT03722680</nct_id>
  </id_info>
  <brief_title>Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.</brief_title>
  <acronym>RILUZOX-01</acronym>
  <official_title>Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy: A Phase II Randomized Study by UNICANCER With the Cooperation of AFSOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a phase II trial, randomized, parallel, double blind, multicenter, comparing riluzole&#xD;
      versus placebo.&#xD;
&#xD;
      The trial population is composed of patients ≥18 years old that have developed stage II/III&#xD;
      colorectal cancer and are eligible for Simplified FOLFOX4 (6-12 cycles) adjuvant&#xD;
      chemotherapy.&#xD;
&#xD;
      The primary objective is to assess the preventive efficacy of riluzole on the severity of&#xD;
      oxaliplatin-induced peripheral neuropathy during the Simplified FOLFOX4 adjuvant chemotherapy&#xD;
      of stage II/III colorectal cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">April 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Riluzole arm: The patient will be taken one tablet (riluzole 50 mg, film-coated tablet) twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo arm: The patient will be taken on tablet (placebo :50 mg, film-coated tablet) Posology, administration and duration of treatment will be equivalent to riluzole group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life questionnaire-chemotherapy-induced peripheral neuropathy (QLQ-CIPN20)</measure>
    <time_frame>3 months afer initiation of oxaliplatin based chemotherapy (1 cycle = 14 days)</time_frame>
    <description>QLQ-CIPN20 Questionnaire (EORTC):&#xD;
Self-reported questionnaire consisting of 20 questions that assess the symptoms and functional limitations of chemotherapy-induced peripheral neuropathy. The questionnaire is divided in 3 subscales: sensory, motor, and autonomic and gives a comprehensive picture of the nature, frequency, and severity of chemotherapy-induced peripheral neuropathy (CIPN). Using a 4-point Likert scale (1 = &quot;not at all,&quot; 2 = &quot;a little,&quot; 3 = &quot;quite a bit,&quot; and 4 = &quot;very much&quot;), patients indicate the degree to which they have experienced sensory, motor, and autonomic symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QLQ-CIPN20</measure>
    <time_frame>At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.</time_frame>
    <description>Self-reported questionnaire consisting of 20 questions that assess the symptoms and functional limitations of chemotherapy-induced peripheral neuropathy. The questionnaire is divided in 3 subscales: sensory, motor, and autonomic and gives a comprehensive picture of the nature, frequency, and severity of CIPN. Using a 4-point Likert scale (1 = &quot;not at all,&quot; 2 = &quot;a little,&quot; 3 = &quot;quite a bit,&quot; and 4 = &quot;very much&quot;), patients indicate the degree to which they have experienced sensory, motor, and autonomic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</measure>
    <time_frame>throughout study completion, assessed up to 43 months</time_frame>
    <description>The NCI-CTCAE v5.0 is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale will assess the severity of sensory neuropathic disorders, this derivative into 5 grades determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) questionnaire</measure>
    <time_frame>At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.</time_frame>
    <description>This self-report questionnaire includes:&#xD;
A body schema&#xD;
The maximum pain, lowest pain, usual pain within the last 15 days (Numerical Numeric rating scales (NRS) 0 to 10&#xD;
Description of current analgesic treatment,&#xD;
An assessment of relief by a percentage scale (0-100%), Assessment of the impact of pain on: mood, relationships with others, walking, sleep, work, happiness the joy - of living, recreation, activities in general (digital scales, rating from 0 [normal] to 10 [no activity]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Douleur Neuropathique 4 (DN4) questionnaire (interview portion)</measure>
    <time_frame>This evaluation will be carried out only if the item 5 of BPI &quot;general pain felt in the last 7 days&quot; is ≥4/10.</time_frame>
    <description>The interview portion of the DN4 questionnaire is a clinician-administered screening tool for neuropathic pain. The questionnaire includes 7 items, grouped into two questions. Each item, is answered as either YES or NO. A final cumulative patient's score is obtained by allocating 1 point for each YES and 0 point for each NO. If the patient's score is ≥3/7, the test is positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Symptom Inventory (NPSI) questionnaire</measure>
    <time_frame>This evaluation will be carried out only if the item 5 of BPI &quot;general pain felt in the last 7 days&quot; is ≥4/10.</time_frame>
    <description>This self-reported questionnaire assesses different neuropathic pain symptoms. The French NPSI includes 12 items that discriminates and quantifies five distinct dimensions of neuropathic pain. Each of these items are quantified on a (0-10) numerical scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-C30 questionnaire (EORTC)</measure>
    <time_frame>At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.</time_frame>
    <description>This self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.&#xD;
The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.&#xD;
All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>From date of randomisation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months.</time_frame>
    <description>Disease Free Survival, defined as the interval between the date of randomization and the date of cancer relapse (local, regional, metastases, second cancer) or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HRQoL score deterioration</measure>
    <time_frame>At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.</time_frame>
    <description>The interval between randomization and deterioration ≥5 points in the HRQoL score as compared to baseline score or death (all causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of chemotherapy dose reductions</measure>
    <time_frame>3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.</time_frame>
    <description>The number of chemotherapy dose reduction caused by severe neuropathy and/or poor tolerance of treatment will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of cumulative dose</measure>
    <time_frame>3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.</time_frame>
    <description>The cumulative dose (mg/m²) of chemotherapy delivered to patients will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of study exit rates</measure>
    <time_frame>3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.</time_frame>
    <description>The study exit rate caused by severe neuropathy and/or poor tolerance of treatment will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of glutamate serum level</measure>
    <time_frame>Glutamate serum level will be dose at inclusion (V0), 3 months (V2), up to 7 months (V3), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.</time_frame>
    <description>Correlation with colorectal cancer tumors/nodes/metastases (TNM) score (and eventually neuropathic symptoms), glutamate plasmatic</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Oxaliplatin-induced Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Posology, administration and duration of treatment will be equivalent to riluzole group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>Riluzole during chemotherapy (oxaliplatin)</description>
    <arm_group_label>Riluzole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged ≥ 18 years old,&#xD;
&#xD;
          2. Eligible patient starting adjuvant oxaliplatin-based chemotherapy (6-12 cycles,&#xD;
             Simplified FOLFOX4) for stage II/III colorectal cancer,&#xD;
&#xD;
          3. Histological or cytological confirmation of colorectal cancer,&#xD;
&#xD;
          4. Performance status (ECOG) ≤2,&#xD;
&#xD;
          5. Normal hematological function (ANC ≥1.5 x 10⁹/L; platelets count ≥100 x 10⁹/L;&#xD;
             hemoglobin ≥9.0 g/dL),&#xD;
&#xD;
          6. Normal hepatic function: total bilirubin ≤1.5 x upper limit of normal (ULN) (unless&#xD;
             documented Gilbert's syndrome); aspartate aminotransferase (ASAT) and alanine&#xD;
             aminotransferase (ALAT) ≤3 x ULN, and gamma-glutamyltransferase (GGT) ≤3 x ULN,&#xD;
&#xD;
          7. Normal renal function: serum creatinine ≤1.5 x ULN,&#xD;
&#xD;
          8. Normal cardiac function: ECG,&#xD;
&#xD;
          9. Patients affiliated to the French national health insurance,&#xD;
&#xD;
         10. Patient must have signed a written informed consent form prior to any study specific&#xD;
             procedures,&#xD;
&#xD;
         11. French language comprehension,&#xD;
&#xD;
         12. Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic cancer,&#xD;
&#xD;
          2. Diagnosis of neuropathy,&#xD;
&#xD;
          3. EORTC QLQ-CIPN20 sensory score &gt;6,&#xD;
&#xD;
          4. Previous neurotoxic chemotherapy treatment,&#xD;
&#xD;
          5. Patients with chronic obstructive pulmonary disease,&#xD;
&#xD;
          6. ALAT/ASAT elevated more than 3 times the normal value,&#xD;
&#xD;
          7. Patients with known allergy or severe hypersensitivity to riluzole or any of the study&#xD;
             drug excipients,&#xD;
&#xD;
          8. Dependence on alcohol or drugs,&#xD;
&#xD;
          9. Psychotic disorders,&#xD;
&#xD;
         10. Women pregnant or breastfeeding,&#xD;
&#xD;
         11. Patients undergoing a measure of legal protection (trusteeship, guardianship ...).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Denis PEZET, MD-PHD</last_name>
    <phone>+ 33 ( 0) 4 73 75 04 94</phone>
    <email>dpezet@chu-clermontferrand.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle RIEGER</last_name>
    <email>i-rieger@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia QUINTIN, MD</last_name>
      <phone>02 41 35 27 00</phone>
      <email>Julia.Quintin@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fayçal HOCINE, MD</last_name>
      <phone>03 44 11 23 09</phone>
      <email>f.hocine@ch-beauvais.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Parzy, MD</last_name>
      <phone>02 31 45 50 16</phone>
      <email>a.parzy@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hia Percy</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien RICARD, MD</last_name>
      <phone>01 41 46 68 85</phone>
      <email>damien1.ricard@intradef.gouv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont -Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Pezet, MD</last_name>
      <phone>04 73 75 04 94</phone>
      <email>dpezet@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique St Côme</name>
      <address>
        <city>Compiègne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kazïs ALDDABAGH, MD</last_name>
      <phone>03 44 92 43 53</phone>
      <email>kais.alddabagh@stcome.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHPSO</name>
      <address>
        <city>Creil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth CAROLA, MD</last_name>
      <email>Elisabeth.Carola@ghpso.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, MD</last_name>
      <phone>03 80 73 77 52</phone>
      <email>FGhiringhelli@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain MANFREDI, MD</last_name>
      <phone>03 80 29 37 50</phone>
      <email>sylvain.manfredi@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Annecy-Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude MONTCHAUD, MD</last_name>
      <phone>04 50 63 66 05</phone>
      <email>amontchaud@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BOUCHE, MD</last_name>
      <phone>03.26.78.71.72</phone>
      <email>obouche@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien BOTSEN, MD</last_name>
      <email>damien.botsen@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO - Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia QUINTIN, MD</last_name>
      <phone>02 40 67 99 33</phone>
      <email>Julia.Quintin@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hia Begin</name>
      <address>
        <city>Saint-Mandé</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Régis FERRRAND, MD</last_name>
      <phone>01 43 98 52 43</phone>
      <email>francoisregisferrand@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Priest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc PHELIP, MD</last_name>
      <email>j.marc.phelip@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Asmahane BENMAZIANE TEILLET, MD</last_name>
      <phone>+33 (0)1 46 25 24 10</phone>
      <email>a.benmaziane@hopital-foch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Riluzole</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

